ArticleAIDS (London, England)2008
Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline.
Article in AIDS (London, England), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Illustration of a measure to combine viral suppression and viral rebound in studies of HIV therapy.Journal of acquired immune deficiency syndromes (1999) · 2015Trial
- Quantifying the Dynamics of HIV Decline in Perinatally Infected Neonates on Antiretroviral Therapy.Journal of acquired immune deficiency syndromes (1999) · 2020Article
- The dynamics of simian immunodeficiency virus after depletion of CD8+ cells.Immunological reviews · 2018Review
- Acute HIV infection presenting as hemophagocytic syndrome with an unusual serological and virological response to ART.BMC infectious diseases · 2016Article
- Molecular clock of HIV-1 envelope genes under early immune selection.Retrovirology · 2016Article
- SPMM: estimating infection duration of multivariant HIV-1 infections.Bioinformatics (Oxford, England) · 2016Article
- HIV-1-Specific CD8 T Cells Exhibit Limited Cross-Reactivity during Acute Infection.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Prevalence and risk factors of HIV and syphilis, and knowledge and risk behaviors related to HIV/AIDS among men who have sex with men in Chongqing, China.Journal of biomedical research · 2016Article
- Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.Journal of virology · 2015Article
- Conceptualizing a Human Right to Prevention in Global HIV/AIDS Policy.Public health ethics · 2012Article
- Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.AIDS (London, England) · 2011Article
- CD8 T-cell proliferative capacity is compromised in primary HIV-1 infection.Journal of acquired immune deficiency syndromes (1999) · 2011Article
- Article
- Antiretroviral therapy initiated soon after HIV diagnosis as standard care: potential to save lives?HIV/AIDS (Auckland, N.Z.) · 2011Article
- Impaired replication capacity of acute/early viruses in persons who become HIV controllers.Journal of virology · 2010Article
- In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells.PLoS pathogens · 2010Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveCompare the initial phases of virologic decay when acute/early and advanced HIV-infected adults are administered the same treatment regimen.
designMathematical modeling of a previously completed prospective treatment pilot study involving treatment-naive patients with early and advanced immunosuppression.
methodsWe analyzed data from a treatment protocol in which 18 individuals with acute or recent HIV-1 seroconversion and six patients with advanced AIDS were administered the same four-drug antiretroviral regimen. Initial treatment responses were compared by fitting a mathematical model to frequent viral load measurements in order to calculate the first and second phase kinetics of viral clearance, and also by comparing viral load suppression over 24 weeks. Patients were also comprehensively compared in terms of protease inhibitor drug levels, HIV-specific immune responses at baseline, and the presence of drug resistance-conferring mutations.
resultsThere was no statistically meaningful difference in first phase clearance of comparable high-level viremia in the two groups, whether protease inhibitor levels were inserted into the model or 100% antiviral drug effectiveness was assumed. In contrast, acute/early patients had inferior sustained responses than advanced patients, reflecting erratic adherence.
conclusionsDespite many years of intervening immune destruction, the initial virologic decay on therapy appears to be the same at the extremes of the HIV disease spectrum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.